<DOC>
	<DOCNO>NCT02116556</DOCNO>
	<brief_summary>Acute alcoholic hepatitis ( AAH ) serious condition one frequent cause Acute-on-Chronic Liver Failure . The current standard therapy ( corticosteroid ) theme debate unsatisfactory many patient ( year mortality : 30 % ) . One main cause death bacterial infection , affect 40-50 % patient 90 day . Intestinal decontamination rifaximin ( nonabsorbable antibiotic ) reduce endotoxemia , improve liver function reduces complication decompensated alcoholic cirrhosis . The Hypothesis/Objective : To assess whether oral decontamination rifaximin prevents development infection associate AAH analyze consequence .</brief_summary>
	<brief_title>Effects Rifaximin Patients With Acute Alcoholic Hepatitis</brief_title>
	<detailed_description>Design : Open multicenter comparative study . A cohort ( n = 66 ) receive rifaximin ( 1200 mg / ) 90 day . Results compare cohort AAH prospectively include observational study . Both group uniform treatment protocol ( include administration corticosteroid standardize treatment complication liver failure ) . Patients monitorized hospital discharge follow-up visit 7 , 30 , 45 , 60 90 day perform . Endpoints : 1 . Primary endpoint : Bacterial infection 90 day . 2 . Secondary endpoint : : 2.1 . Liver function test 2.2 . Levels endotoxemia 2.3 . Complications liver cirrhosis . 2.4 . Survival</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Patients â‰¥18 &lt; 70 year age . Active alcohol abuse excessive alcohol consumption prior admission define &gt; 50 g per day men &gt; 40 g per day woman . Jaundice ( Bilirubin &gt; 2 mg/dl ) 3 month . Clinical suspicion Alcoholic Hepatitis modify Maddrey 's Discriminant Function &gt; 32 point . Hypersensitivity Rifaximin Advanced Chronic Terminal illness . Advanced Chronic illness define : condition evolve clinical stage limit patient 's functional status ( eg , heart failure NYHA &gt; II , COPD PCO2 &gt; 50 mmHg PO2 &lt; 60 mmHg , stroke disable neurological disease , disable uncontrolled oncological condition , etc ... ) . Terminal illness define clinical condition survival expectancy le 3 month Hepatocellular carcinoma ( previously diagnose ) beyond Milan 's criterion . Complete portal vein thrombosis ( previously diagnose ) . Autoimmune liver disease . Hepatitis B C HIV infection ( antiHCV , surface HBV antigen antiHIV positive ) . Pregnancy nursing . Use Rifaximin previous 2 month . Treatment Pentoxifylline . Lack informed consent . Removal criterion : Lack histological confirmation Alcoholic Hepatitis first 7 day inclusion . Because nondiagnostic tool diagnose alcoholic hepatitis , histological confirmation require patient ( preferably transjugular biopsy ) : alcoholic hepatitis diagnose presence follow histologic feature : Hepatocellular damage ( eg , hepatocyte ballooning presence MalloryDenk body ) . Inflammatory infiltrate ( predominantly polymorphonuclear cell ) . Pericellular sinusoidal fibrosis . Hepatocellular carcinoma beyond Milan 's criterion diagnose first 7 day inclusion . Complete portal vein thrombosis diagnose first 7 day inclusion . Protocol violation . Severe adverse event directly relate Rifaximin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alcoholic Hepatitis</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Acute-on-Chronic Liver Failure</keyword>
</DOC>